ReviewLife (Basel, Switzerland)2023
Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07013552 (Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review.The Journal of antimicrobial chemotherapy · 2026Pooled it
- The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused byOpen forum infectious diseases · 2025Trial
- Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring.JAC-antimicrobial resistance · 2026Article
- Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study.Pharmaceutics · 2026Article
- Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study.Infectious diseases and therapy · 2026Article
- Oritavancin for Gram-Positive Bone and Joint Infections: A Comprehensive Review of the Literature.Antibiotics (Basel, Switzerland) · 2026Review
- Oritavancin as rescue therapy in severe methicillin-resistant Staphylococcus aureus pneumonia: A case report.Respiratory medicine case reports · 2026Article
- Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review.Antibiotics (Basel, Switzerland) · 2025Review
- Legends, dogmas, presumptions, and demystifications in antibiotic therapy.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Infectious diseases and therapy · 2025Review
- Vascular Graft Infections Due toMicroorganisms · 2025Review
- The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.Journal of clinical medicine · 2025Review
- Long-Acting Antibiotics: New Opportunities Beyond Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)!Antibiotics (Basel, Switzerland) · 2025Article
- Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?Heliyon · 2025Article
- ORItavancin as a therapeutic regimen for Cardiac Implantable Electronic Devices infections with multidrug-resistant Gram-positive cocci (ORI-4-CIEDi) pilot study: rationale and design.Cardiology journal · 2025Article
- The emerging challenge ofClinical microbiology reviews · 2024Review
- Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes.JAC-antimicrobial resistance · 2024Article
- Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Antibiotics with antibiofilm activity - rifampicin and beyond.Frontiers in microbiology · 2024Review
- Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM).IDCases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oritavancin is a long-acting lipoglycopeptide with in vitro activity against Gram-positive pathogens, as well as good bactericidal activity and sterilisation ability in biofilm. It has been approved for acute bacterial skin and skin structure infections (ABSSSI), but recent reports have demonstrated possible off-label uses, such as for vancomycin resistant enterococci (VRE), deep-seated infections including those involving prosthetic material and invasive infections. The aim of this work is to review the uses of oritavancin outside of ABSSSI, focusing on its real-life applications on infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans, as well as possible future applications. We performed a narrative review, collecting the literature published between 1 December 2002 and 1 November 2022 on PubMed and the Cochrane Library using the term 'oritavancin'. Available studies have shown how effective it is in different settings, suggesting an opportunity for step-down strategies or outpatient management of infections requiring a long duration of antibiotic treatment. So far, evidence is still scarce, and limited to a few studies and case reports, mostly focusing on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.